LOL Hartland. Quiet times right now for sure waiting for the next news from Resverlogix (and Zenith too). I sure hope we hear about the start of US patients enrolling in BETonMACE real soon. I also hope that they are close to announcing some kind of plan to raise funds to fund the Renal trial, Fabry trial etc. Renal trial has been delayed and delayed. They need to get those funds and start that very promising trial ASAP. My guess is no sample size re-estimation analysis for BETonMACE until Q2, but I'd love to be surprised and hear something this quarter.

BTW, Resverlogix is presenting at American College of Cardiology 2018 conference on March 11, 2018. Abstract is embargoed at this time, but here is the link to the presentation info:

Session 1247 - Interventional Cardiology: Cutting-Edge Translational and Pre-Clinical Research

1247-298 / 298 - Apabetalone (RVX-208) Modulates Epigenetic Processes in Monocytes and Endothelial Cells Affected by Diabetes Mellitus and Diet That Enhance Risk of Cardiovascular Disease (CVD)